Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Big jump in traded volume on NYSE today...over 535% above 65 day average. Interesting.....it's been around 25% over past 2 weeks.
At our current lowly price, the market values ONT at £983m, but when you factor in they have zero debt and £480m in cash/cash equivalents then the market have a £500m value essentially.
With its cash burn around £70m py, it has a cash runway of about 6-7 years, but expects to be profitable in 2027, with revenues expected to be 6-15% higher this year than last, which was £169.7m in 2023.
Someone is mopping up these cheap shares, next few weeks I'm expecting a continuous rise into the £1.40's region, especially as the June date gets closer
And another whopping uncrossing trade today. That's £0.75m yesterday and £0.88m today. Things are shaping up as the few shorters bail out.
BioMerieux SA and Illumina could both be interested enough to secure control here. That would certainly perk up wider interest. Undervalued significantly imo given huge potential and fact that bioMerieux SA payed twice this price per share for its c 7%.
This little holding could have interesting significance also from June 6th. Very undervalued and ideal tech for big pharma.
I agree directors purchased over half million pounds between them at around £1,28, only 6 weeks back.
I honestly believe this hugely innovative company is at huge risk to be snapped UP by someone like Illumina who are struggling for growth and could view Oxford as future competitor due to their superb portable devices, long read technologies and growing user base.
Don't forget BioMerieux agreed to buy 3.5% at 2.38p last October; and very substantial, recent director buys at £1 below that.
I see a rare historic opportunity at these levels.
Yes I agree. We could see a rapid rise back above 200p as we close in on the 6th June. For those not aware directors will right to veto a takeover so we will be very vulnerable at these prices. BUY
Seems we finally have upward momentum, how it ever was pushed sub £1, I'll never understand, it's no wonder some UK tech companies considering moving to the States to be listed....June 6th is the date when this company loses its IPO protection and can be snapped UP by predators
Nice tidy £0.75m uncrossing trade there.
Deutsche Bank initiates Oxford Nanopore with 'buy' - target 190 pence
£15m dark pool trade yesterday at £0.97. Feels bullish
Excellent piece on YouTube called Illumina vs Oxford Nanopore | Long-read hacking by Bad Genome
Always a good sign, adding to the big director buys last month.
This becomes a more interesting share at the end of the month when the no takeover protection the company put in place since IPO launch (to enable company to mature without cheap takeover) ends...making them in my book a target for the likesif Illumina who faked a long reads process, but it's not in same league as Oxford long reads
Director buying.
Well let's hope we never see 90s again, trying to consolidate above £1, patience is key, I've a strong feeling we will look back on this price in shock it was ever this low
Sadly with UK biotechs while often the science is great the managers are self serving and third rate. One has to wait for a bid or JV from a major to see the science become a product.
36 months from the bottom wherever that is.
I’ve had funnier toothaches than watching this stock!
Will it ever get back to 2 / 3 quid?
I always have a saying if you think it cant fall any further it normally does
ONT should merge with Pacific Bio - who are roughly the same market cap but have actually underperformed us! ONT could reverse in and pick up a US listing at the same time….
Nice to see a little bounce before close. Let’s hope it holds. Crazy this was 2:80 only months ago
60-70p bottom is my guess
Is not a nice feeling, I hope we can finish above the 1 pound mark by tomorrow.